Backed by Intel s Life Science Largesse, Concurrent Develops In Silico Discovery Tools | GenomeWeb

Concurrent Pharmaceuticals, an early-stage drug discovery firm based in Fort Washington, Pa., last week announced that it has entered into a collaboration with Intel to develop machine-learning tools for computational drug discovery. In addition, Intel’s strategic investment arm, Intel Capital, joined the company’s previous investors — Prospect Venture Partners, Venrock Associates, and New Enterprise Associates — in a Series B preferred stock financing round totaling $15 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.